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Atypical 7-transmembrane receptors, often called
decoy receptors, act promiscuously as molecular
sinks to regulate ligand bioavailability and conse-
quently temper the signaling of canonical G pro-
tein-coupled receptor (GPCR) pathways. Loss of
mammalian CXCR7, the most recently described
decoy receptor, results in postnatal lethality due to
aberrant cardiac development and myocyte hyper-
plasia. Here, we provide the molecular underpinning
for this proliferative phenotype by demonstrating
that the dosage and signaling of adrenomedullin
(Adm, gene; AM, protein)—a mitogenic peptide
hormone required for normal cardiovascular devel-
opment—is tightly controlled by CXCR7. To this
end, Cxcr7/ mice exhibit gain-of-function cardiac
and lymphatic vascular phenotypes that can be
reversed upon genetic depletion of adrenomedullin
ligand. In addition to identifying a biological ligand
accountable for the phenotypes of Cxcr7/ mice,
these results reveal a previously underappreciated
role for decoy receptors as molecular rheostats in
controlling the timing and extent of GPCR-mediated
cardiac and vascular development.
INTRODUCTION
The precise spatiotemporal dosage of mitogenic and chemo-
tactic factors is critical for the proper organization and develop-
ment of organ systems. While the concentration of ligands often
differs between tissues and developmental stages, the bioavail-
ability of ligands within local microenvironments must also be
controlled at a cellular level. Thus, cells can express molecular
sink receptors, which in an autocrine or paracrine manner,
sequester ligand away from canonical signaling receptors,
thereby driving important developmental processes like neuro-
genesis, angiogenesis, chemotaxis, and cellular proliferation
(Graham et al., 2012; Nibbs and Graham, 2013). Molecular sink
receptors include atypical chemokine receptors, also known as528 Developmental Cell 30, 528–540, September 8, 2014 ª2014 Elsedecoy receptors, which belong to the larger family of 7-trans-
membrane receptors. Decoy receptors act as molecular sinks
by binding, internalizing, and degrading a wide range of ligands
independent of G protein coupling (Graham et al., 2012). CXCR7
is the most recently described decoy receptor and has been
extensively studied for its role as a CXCL12/SDF-1 receptor (Bol-
dajipour et al., 2008; Naumann et al., 2010; Thelen and Thelen,
2008), particularly in tumor cell migration and cancer progression
(Duda et al., 2011; Sa´nchez-Martı´n et al., 2013).
However, prominent roles for CXCR7 during normal develop-
ment and physiology have also been recently appreciated. In
zebrafish, the expression and molecular sink functions of
CXCR7 in trailing cells of the posterior lateral line primordium
allow for a CXCL12 chemotactic gradient to be established
and sensed by the leading primordial germ cells that express
CXCR4, the canonical SDF-1/CXCL12 receptor (Dambly-Chau-
die`re et al., 2007; Dona` et al., 2013; Valentin et al., 2007; Venki-
teswaran et al., 2013). In this instance, CXCR7 exerts its decoy
activities over a wide region to help coordinate and guide the
migration of multicellular tissue structures.
However, the decoy activities of CXCR7 can also occur in a
cell-autonomous fashion. For example, the coexpression of
CXCR7 within migrating cortical neurons allows for the
continued sensitization and chemotactic signaling of CXCR4—
rather than receptor desensitization and downregulation that
would typically occur within an environment of high CXCL12
ligand (Sa´nchez-Alcan˜iz et al., 2011; Wang et al., 2011).
Recently, CXCR7 expression in endothelial cells has also been
shown to regulate circulating levels of ligands, suggesting that
CXCR7 expression in vessels may not only affect signaling
events in a microenvironment, but systemically as well (Beraho-
vich et al., 2014).
Due to these well-described roles in the CXCL12/CXCR4
signaling axis, Cxcr7/ mice were expected to exhibit pheno-
types that might resemble gain-of-function mutations for the
CXCL12/CXCR4 signaling axis. However, Cxcr7/ mice have
unexpected phenotypes including cardiomyocyte hyperplasia
and postnatal lethality associated with gross cardiac enlarge-
ment and cardiac valve defects (Gerrits et al., 2008; Sierro
et al., 2007; Yu et al., 2011). Because decoy receptors typically
bind and sequester multiple ligands, it has been difficult to
discern which ligand may be causally related to the develop-
mental cardiac defects of Cxcr7/ mice. In this regard, wevier Inc.
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putative receptor for adrenomedullin (Adm, gene; AM, protein),
a 52 amino acid mitogenic peptide hormone critical for cardiac
and lymphatic vascular development (Caron and Smithies,
2001; Dackor et al., 2006; Dunworth et al., 2008; Fritz-Six
et al., 2008). AM binds RDC1/CXCR7 with a Kd of 1.9 3
107 M, similar to CLR when associated with RAMPs (Kapas
and Clark, 1995). Importantly, we have recently shown that
genetic overexpression of AM ligand in Admhi/hi mice results in
gross cardiac enlargement due to cardiac hyperplasia during
embryogenesis (Wetzel-Strong et al., 2014), which closely phe-
nocopies the dysmorphic cardiac hyperplasia of Cxcr7/mice.
We therefore sought to address whether a principal function of
CXCR7 may involve controlling the dosage of AM ligand during
development, first focusing our attention on the cardiac hyper-
plasia. In the course of our studies, we also discovered lymphatic
vascular defects in Cxcr7/mice, which are consistent with the
prominent role that AM signaling plays in driving normal lym-
phangiogenesis (Dunworth et al., 2008; Fritz-Six et al., 2008;
Hoopes et al., 2012; Karpinich et al., 2011). In addition to identi-
fying a biological ligand that is causally associated with the
Cxcr7/ phenotypes, the results described here elucidate a
role for decoy receptors as molecular rheostats that control
normal cardiac and lymphatic vascular development.
RESULTS
Gene Expression of Cxcr7 and Adm Are Coupled in the
Heart and Lymphatic Endothelium
Historical ligand binding data (Kapas and Clark, 1995) and more
recent findings show a downregulation of Adm gene expression
in Cxcr7/ mice (Sierro et al., 2007) and strongly support the
existence of this ligand-receptor pair. Considering the well-
established function of CXCR7 as a decoy receptor, we pre-
dicted that expression levels of Cxcr7 may homeostatically
increase under conditions of increased AM peptide. To further
evaluate whether this interaction exists, we measured the
expression of Cxcr7 in hearts of Admhi/hi mice which have a
genetically engineered, 3-fold increase in Adm gene expres-
sion (Wetzel-Strong et al., 2014). Indeed, utilizing quantitative
real-time PCR (qRT-PCR), we identified a potent 2.5-fold
upregulation of Cxcr7 gene expression in Admhi/hi cardiac tis-
sue compared to that of wild-type littermates (Figure 1A).
Conversely, loss of Adm expression in isolated endothelial
cells resulted in a nearly 5-fold reduction in Cxcr7 expression
(Figure 1A).
We also found thatCxcr7 is expressed at high levels in isolated,
adult lymphatic vessels—a tissue where AM peptide plays
important roles (Figure S1A available online). Consistently,micro-
array analysis of cultured, human lymphatic endothelial cells
(LECs) showed that expression of the human CXCR7 gene
(aka ACKR3 or CMKOR1) was one of the ten most significantly
induced genes within 1 hr of 10 nM AM treatment (p = 2.5E–07)
(Figure 1B; Table S1). This finding was further confirmed by
qRT-PCR, revealing a 4-fold increase inCXCR7 gene expression
following 1 hr and 24 hr of AM treatment (Figure 1C). Pretreat-
ment with AM22–52, a CLR/R2 antagonist, significantly reduced
this AM-mediated increase (Figure 1C), demonstrating that the
upregulation of CXCR7 gene expression is modulated throughDevelopmethe canonical AM receptor. Collectively, these data indicate
that CXCR7 and ADM gene expression levels are coupled within
tissues where AM peptide plays important developmental and
physiological roles. Because excess AM, either by genetic over-
expression in vivo or exogenous treatment in vitro, triggered an
increase in CXCR7 expression, we next tested directly the hy-
pothesis that CXCR7 serves as a decoy receptor to modify AM
concentration.
CXCR7 Scavenges AM Peptide and Dampens Canonical
AM Signaling
Using a classical scavenger assay, CXCR7-expressing
HEK293T cells were treated with biotinylated-AM1–52, and ali-
quots of media were collected over time to determine the re-
maining levels of AM peptide within the media. While the levels
of biotinylated-AM1–52 in the media of vector-transfected control
cells remained unchanged, CXCR7-expressing cells rapidly and
steadily depleted AM peptide from the media to levels that were
statistically lower than control cells by the conclusion of the time
course (Figures 1D and 1E). These data demonstrate the ability
of CXCR7 to modulate AM ligand concentrations exogenously
in a controlled in vitro system.
To determine whether this scavenging of AM peptide by
CXCR7 was conserved in vivo, we compared AM staining in
cardiac tissue of wild-type mice and Cxcr7/ mice, which har-
bor an insertional GFP reporter within the targeted allele. First,
we noted that expression of the GFP reporter was enriched
within the epicardium and the endocardium surrounding the
trabeculae and weakly expressed in the compact zone (Fig-
ure 1F). Second, the staining pattern of receptor expression
was spatially juxtaposed and/or overlapping with the most
prominent sites of AM peptide expression, including the epicar-
dium and trabeculae (Figure 1G) (Wetzel-Strong et al., 2014).
Remarkably, we found a significant 30% increase in the relative
staining intensities of AM peptide in the epicardium and trabec-
ulae of Cxcr7/ mice compared to wild-type littermates (Fig-
ures 1H–1K), but no changes within the compact zone where
levels of Cxcr7 reporter expression were modest (Figure 1L).
These findings indicate that spatially juxtaposed and/or over-
lapping expression of CXCR7 and AM during cardiac develop-
ment is essential for scavenging AM peptide in cardiac tissue
in vivo.
Activation of the canonical AM-receptor complex, CLR and re-
ceptor activity modifying protein 2 (RAMP2), elicits an increase in
cAMP and subsequent downstream activation and phosphoryla-
tion of ERK (Fritz-Six et al., 2008). Utilizing a highly sensitive
bioluminescence resonance energy transfer (BRET) reporter
system (Barak et al., 2008; Ponimaskin et al., 2007), we found
that HEK293T cells that overexpress CXCR7 failed to accumu-
late cAMP upon AM stimulation—a finding consistent with the
lack of G protein coupling by decoy receptors (Figure S1B). As
expected, AM treatment of CLR/RAMP2-expressing cells re-
sulted in a potent accumulation of cAMP (Figure S1B) and
pERK:tERK upregulation (Figures 1M, 1N, and S1C). Impor-
tantly, while AM did not elicit a pERK:tERK upregulation in cells
transfected with CXCR7 alone, the CLR-RAMP2-mediated acti-
vation of pERK:tERK was markedly abrogated when cells were
cotransfected with CXCR7 (Figures 1M and 1N). These in vitro
signaling assays demonstrate that CXCR7 can act as antal Cell 30, 528–540, September 8, 2014 ª2014 Elsevier Inc. 529
(legend on next page)
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pERK:tERK signaling.
The effects of CXCR7 on dampening pERK:tERK signaling
were also confirmed in vivo, where we noted significant accumu-
lation of pERK staining in dermal lymphatic vessels of postnatal
day 1 Cxcr7/ tail skin compared to wild-type littermates (Fig-
ures S2A–S2D). Furthermore, we also observed a significant
increase in the pERK staining in the lymphatic sac of E13.5
Cxcr7/ embryos compared to wild-type animals (Figures
S2E–S2J). These in vivo data from a genetic loss-of-function
model aptly reciprocate the findings from the in vitro gain-of-
function experiments and furthermore demonstrate that loss of
Cxcr7 expression influences ERK phosphorylation on a tissue
level.
Cxcr7 Is Dynamically Expressed in Lymphatic
Endothelium during Development
Previous studies have reported that nearly one third of adult
dermal lymphatic vessels express CXCR7 (Neusser et al.,
2010), but the spatiotemporal expression of CXCR7 during
developmental lymphangiogenesis has yet to be described.
Using the GFP-targeted Cxcr7+/ reporter allele, we found
Cxcr7 expression colocalized with the lymphatic markers
LYVE1 (Figures 2A–2C), Prox1 (Figures 2G–2I), and podoplanin
(Figures 2I–2L). At E11.5, lymphatic progenitor cells are arranged
in a stereotypically-polarized fashion within the jugular vein (JV)
and express Cxcr7 (Figures 2A–2F, white arrows, 2I, and 2L).
Interestingly, we often noted that Cxcr7 expression is tempo-
rarily reduced as the lymphatic progenitors begin to migrate
away from the JV (Figures 2F and 2I, asterisks)—underscoring
the dynamic expression of the decoy receptor in areas of active
cell migration. As lymphatic cells coalesce to form the lymph
sacs (LS) between E11.5–E13.5, Cxcr7 was again expressed in
some lymphatics, which were identified by LYVE1 and podopla-
nin colabeling (Figures 2J–2O). Cxcr7 was also persistently
expressed in the JV cells directly adjacent to the LS (Figures
2P–2R, white arrowheads), consistent with recently published
studies demonstrating a paracrine function for decoy receptors
(Moissoglu et al., 2014; Venkiteswaran et al., 2013). In summary,
Cxcr7 is highly and dynamically expressed within lymphatic pro-
genitors and early lymphatic vessels at the time of nascent lym-
phangiogenesis, which also spatiotemporally correlates with the
proliferative effects of AM during lymphatic development.Figure 1. CXCR7 Scavenges AM, Dampens AM-Mediated ERK Phosph
(A) Cxcr7 expression in cardiac tissue of Adm+/+ and Admhi/hi mice (n = 6) and is
(B) The nine most significantly upregulated and four most significantly downregu
(C) CXCR7 expression in vehicle and 10 nM AM-treated hLECs at 15 min, 1 hr, a
(D and E) Representative western blots probed for biotin (D) and quantitation of b
cells in three independent experiments.
(F and G) Cxcr7 and AM staining in E13.5 Cxcr7/ cardiac tissue with epicardia
(H and I) AM staining of E13.5 Cxcr7+/+ and Cxcr7/ cardiac tissue. White arrow
highlight the cardiac trabeculae. Images were obtained at the same exposure and
measuring the integrated density of staining using ImageJ software (n = 3–5). Sc
(J–L) Quantitation of AM staining intensity in Cxcr7+/+ (n = 3) versus Cxcr7/ (n =
zone. Staining intensity is expressed as arbitrary units of integrated density as m
(M and N) Representative western blot (M) and quantitation of change (N) in pER
R2+CXCR7-expressing HEK293T. Quantitation was calculated using three indep
In (A)–(L), data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.00
See also Figures S1 and S2 and Table S1.
DevelopmeCxcr7–/– Mice Have Enlarged, Blood-Filled
Lymphatic Sacs
We have previously established that AM signaling is required for
normal LEC proliferation at E13.5 (Fritz-Six et al., 2008). Thus, we
investigatedwhether loss ofCxcr7, whichwe hypothesize to be a
molecular rheostat for AM, disrupts lymphangiogenesis at this
point during embryogenesis. Indeed, 10% of Cxcr7/ mice
exhibited visible interstitial edema upon dissection at midgesta-
tion (Figures 3A, white arrows, 3B, and 3C, black arrows).
Histological evaluation further revealed that 10%–15% of
Cxcr7/ mice displayed interstitial edema, particularly within
the thoracic regions surrounding the developing jugular lym-
phatics. Additionally, we noticed abnormal LS morphology,
includingmarkedly enlarged and dysmorphic LS inCxcr7/ em-
bryos compared to wild-type littermate embryos (Figures 3D–
3F). Utilizing computerized morphometry to calculate LS and
JV area, we found that the LS:JV ratio of null mice was increased
4-fold compared toCxcr7+/+ mice (Figure 3G). Some sections re-
vealed failure of the LS to separate from the JV, with prominent
platelet thrombi (Figure 3F, black arrows). Moreover, Cxcr7/
lymphatic vessels exhibited remarkable blood (Figure 3E, aster-
isks) and proteinaceous deposits (Figure 3E, arrowheads), which
are phenotypes commonly ascribed to pathologic lymphangio-
genesis and lymph stasis in several mouse models (Bertozzi
et al., 2010; Murtomaki et al., 2013). A scoring rubric to assess
the severity of lymphatic defects showed that LS of Cxcr7/
embryos had significantly more blood and protein accumulation
compared to control mice (Figures 3H and 3I). Taken together,
these results demonstrate that loss of Cxcr7 during embryonic
development results in aberrant LS formation.
To determine whether the blood accumulation in the LS was
due to improper development or structure of the lymphovenous
valves, we stained frontally sectioned embryos with the
lymphatic markers Prox1 and podoplanin. We observed no
structural differences between Cxcr7+/+ and Cxcr7/ lympho-
venous valves (Figures S3A and S3B), with both wild-type and
mutant animals exhibiting characteristic high-Prox1 staining on
the valve leaflet. We next consideredwhether the blood accumu-
lation in Cxcr7/ lymph sacs might be associated with preco-
cious development of the lymphatic sac. As expected, E11.5
wild-type embryos exhibited polarization of LYVE1+ lymphatic
progenitors within the jugular vein. However, some Cxcr7/
littermate embryos exhibited premature migration of LECs fromorylation In Vitro, and Reduces AM Peptide Levels In Vivo
olated endothelial cells of Adm+/+ and Adm/ mice (n = 3).
lated genes in human LECs (hLECs) treated with 10 nM AM for 1 hr.
nd 24 hr, and AM22–52, AM, and [AM22–52+AM] for 4 hr.
iotinylated-AM1–52 (E) depletion over 8 hr by either CXCR7- or EV-expressing
l colocalization (white arrows).
s highlight epicardium, CZ identifies the compact zone, and white arrowheads
the amount of AM expressed in the three regions of the heart was assessed by
ale bars represent 100 mM.
5) animals in three regions of the heart, trabeculae, epicardium, and compact
easured by ImageJ.
K:tERK between vehicle and 10 nM AM-treated CXCR7-, CLR/R2-, and CLR/
endent experiments run on the same gel.
1.
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Figure 2. Cxcr7 Is Dynamically Expressed
in Lymphatic Endothelium during Develop-
ment
(A–C) Cxcr7 and LYVE1 colocalize in the JV of
E11.5 Cxcr7+/ animals.
(D–F) Higher magnification of the LYVE1 positive
portion of the JV. White arrows highlight areas of
Cxcr7 and LYVE1 colocalization. Asterisk high-
lights migrating LYVE1 positive, Cxcr7 negative
cells.
(G–I)Cxcr7 and Prox1 colocalize in the JV of E11.5
Cxcr7+/ animals. Asterisks highlight migrating
Prox1 positive, Cxcr7 negative LECs.
(J–O)Cxcr7 and lymphatic markers (J, podoplanin;
M, LYVE1) colocalize in the LS (white arrows) of
E11.5 (J)–(L) and E13.5 (M)–(O) Cxcr7+/ animals.
(P–R) Cxcr7 is also expressed in cells of the JV
directly adjacent to the LS. White arrowheads
highlight Cxcr7 expression in the JV. Scale bars
represent 50 mM.
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filled lymph sacs (Figures S3C and S3D)—a process that typi-
cally occurs 1–2 days later in development. Thus, we reasoned532 Developmental Cell 30, 528–540, September 8, 2014 ª2014 Elsevier Inc.that the likely cause of blood accumula-
tion in the Cxcr7/ mutants is preco-
cious lymph sac formation prior to proper
separation of the blood and lymphatic
vascular systems.
Loss of CXCR7 Enhances LEC
Migration In Vivo and In Vitro
We next sought to determine whether
loss of Cxcr7 affected lymphangiogene-
sis in other lymphatic vascular beds. At
E18.5, staining ofCxcr7/ cardiac tissue
revealed increased LYVE1+ vessels on
the surface of the heart (Figure 4A). This
increase might be expected due to the
cardiac hyperplasia inCxcr7/ embryos.
Nevertheless, when normalized to total
surface area of the heart, null animals
exhibited a 20% increase in cardiac
lymphatic vessels on the ventral surface
of the heart (Figure 4B). Higher power
examination of the cardiac lymphatic ves-
sels of Cxcr7/ animals revealed a
disruption of branching complexity and
lacunae number (Figures S4A–S4F), as
well as an extensive network of lymphatic
vessels in the curvature of the outflow
tract on cardiac dorsal-surface (Fig-
ure S4C, arrows) that were not present
in wild-type mice. Additionally, these
LYVE1+ vessels tended to extend farther
down the apex of the heart in Cxcr7/
embryos, suggesting that Cxcr7 also af-
fects LEC migration (Figures 4A and 4C).
To elucidate whether loss of CXCR7 is
directly involved in enhancing AM-medi-ated downstream signaling pathways and cellular migration,
we utilized shRNA lentiviral vectors to achieve 80% knockdown
of CXCR7 in human LECs (Figure 4D). We first used a scavenger
Figure 3. Cxcr7–/– Embryos Have Enlarged
Blood-Filled Lymphatic Sacs and Interstitial
Edema
(A–C) Some Cxcr7/ embryos exhibit interstitial
edema at E13.5 [white (A) and black (C) arrows].
(D–F) Cxcr7/ embryos exhibit enlarged lymph
sacs filled with blood (asterisks) and proteina-
ceous deposits (arrowheads) at E13.5. (F) In some
Cxcr7/ embryos, the LS fails to separate from
the JV properly. Platelet thrombi are highlighted by
arrowheads.
(G–I) Quantitation of the LS:JV ratio (t test) and
blood and protein accumulation (Mann-Whitney
U test) in the LS of Cxcr7/ embryos (n = 10)
compared to wild-type controls (n = 5). A detailed
description of the scoring rubric is provided in the
methods section. Data are represented as mean ±
SEM. *p < 0.05, **p < 0.01.
See also Figure S3.
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less AM than control cells, resulting in increased AM available
to interact with the signaling receptor, CLR/R2 (Figures S5A
and S5B). Next, we showed that knockdown of endogenous
CXCR7 in LECs results in an increase in AM-mediated ERK
phosphorylation, with CXCR7 shRNA-infected LECs exhibiting
a potent upregulation in pERK:tERK ratios in response to AM
treatment, whereas control cells did not (Figure S5C).
These CXCR7 knockdown cells were then used to evaluate
whether loss of CXCR7 enhances AM-mediated LEC migra-
tion. Using an in vitro scratch assay, we showed that AM
promotes LEC migration, because AM-treated control cells
migrated 41% more than vehicle-treated cells (Figures 4E
and 4G). Furthermore, AM treatment of CXCR7 knockdown
cells caused the cells to migrate into the scratch 66% more
than vehicle-treated cells (Figures 4F and 4H). Moreover,
percent migration of AM-treated CXCR7 knockdown LECs
was significantly increased above all other conditions (Fig-
ure 4I). These scratch assay findings were fully recapitulated
using a transwell migration assay (Figure 4J). Finally, the effect
of CXCR7 on AM-mediated cell migration was corroborated
using an overexpression model. As expected, AM treatment
of CLR/RAMP2-expressing HEK293T cells resulted in in-
creased migration across a transwell. However, this migration
was abrogated when cells were cotransfected with a CXCR7
expression plasmid (Figure 4K). Collectively, these data show
that CXCR7 expression modulates AM-mediated downstream
signaling activity, with knockdown of endogenous CXCR7Developmental Cell 30, 528–540, Sincreasing and overexpression of
CXCR7 reducing AM-mediated cellular
migration.
Dermal Lymphatic Vessels of
Cxcr7–/– Animals Are Enlarged, with
Less Branching Complexity
Wealso observedmorphological changes
in the dermal lymphatic vessels of
Cxcr7/ mice. Interestingly, although
there was stochastic expression ofCxcr7 in dermal lymphatic vessels (Figure S6), we consistently
observed Cxcr7 expression in blood vessels, again suggesting
that non-cell-autonomous expression of Cxcr7 can affect lym-
phangiogenesis. While the dermal lymphatics of wild-type ani-
mals formed a highly-structured lattice network, those of
Cxcr7/ embryos failed to extend and connect to neighboring
vessels, resulting in fewer ring-like structures or lacunae (Figures
5A and 5B, asterisks). For example, control lymphatic capillary
networks comprised between six to eight lacunae per image,
but the lymphatic network of Cxcr7/ skin consisted of only
four to five lacunae per image (Figure 5C). Quantitation of the
number of branch points also revealed a significant reduction in
branching complexity, from23.2 to 16.3 per image, between con-
trol and Cxcr7/ dermal lymphatics (Figure 5D) (image area
measured 132,800 mm2). Additionally,Cxcr7/ dermal lymphatic
vessels were enlarged compared to littermate controls (Figures
5E–5I, yellow dashed line). The junctional area where vessels
coalesce to form a branch point was also increased (Figures
5G, 5H, and 5J, yellow solid line).
Previously published studies demonstrate that this type of in-
crease in vessel diameter and decreased branching complexity
is consistent with a hyperplastic phenotype (Coxam et al.,
2014; James et al., 2013), suggesting that loss of CXCR7 results
in hyperproliferation of LECs.We therefore sought to determine if
this hyperplastic phenotype of Cxcr7/ dermal lymphatics
could be attributed to increased AM-mediated LEC prolifera-
tion—a biological effect of AM which has been demonstrated
by our group and others (Fritz-Six et al., 2008; Jin et al., 2008;eptember 8, 2014 ª2014 Elsevier Inc. 533
Figure 4. Loss of CXCR7 Enhances Cardiac
Lymphangiogenesis by Promoting AM-
Mediated Cellular Migration
(A) View of ventral side of whole mount hearts of
E18.5 embryos stained with the lymphatic marker
LYVE1.
(B and C) Quantitation of LYVE1 staining normal-
ized to surface area (B) and LEC migration down
the apex of the hearts (C) (n = 3).
(D) CXCR7 knockdown in LECs by two shRNA
lentiviral constructs.
(E–H) Control or CXCR7 knockdown LECs
treated with vehicle (E and F) or 10 nM AM at 18 hr
(G and H). Migration from the time of scratch (T = 0)
was measured. Scale bars represent 100 mM.
(I) Quantitation of LEC migration in CXCR7
knockdown and control LECs.
(J and K) Quantitation of transwell migration of
CXCR7 knockdown LECs treated with vehicle
or 10 nM AM (J), and empty vector (EV),
CXCR7-, CLR/R2-, and CLR/R2+CXCR7-ex-
pressing HEK293T cells treated with 10 nM AM.
In (A)–(K), data are represented as mean ± SEM.
*p < 0.05, **p < 0.01, ****p < 0.001. See also Figures
S4 and S5.
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observed a 50% increase in proliferation in AM-treated CXCR7
knockdown LECs compared to AM-treated control cells (Fig-
ure 5K). Collectively, these data demonstrate that loss of
CXCR7 promotes AM-mediated LEC lymphangiogenesis by
enhancing both migration and proliferation in vivo and in vitro.
Genetic Titration of Adm Changes Cxcr7–/– Survival
We next sought to determine whether the phenotypes of
Cxcr7/ embryos could be causally associated with AM ligand
concentration in vivo. To test this, we employed a genetic
approach, depicted in Figures 6A and 6C, which allowed for
the generation of Cxcr7 gene-targeted mice on a titrated back-
ground of AM ligand that ranges from 50% to 300% wild-type
levels. Adm+/ mice express 50% of wild-type levels of Adm
mRNA and peptide and exhibit exacerbated cardiovascular
damage, reduced female fertility, and defective lymphatic func-534 Developmental Cell 30, 528–540, September 8, 2014 ª2014 Elsevier Inc.tion (Caron and Smithies, 2001; Li et al.,
2006; Nikitenko et al., 2013). Admhi/hi ani-
mals survive to adulthood, but exhibit
profound cardiac hyperplasia during
development (Wetzel-Strong et al.,
2014). Therefore, we were confident that
the effective dosage of AM peptide
achieved with the AM ‘‘gene titration’’
mice was within a range that would have
significant biological impact on lymphatic
and cardiac development.
First, because we noted some embry-
onic lethality in Cxcr7/ animals in the
genetic reduction experiment, we asked
whether Adm haploinsufficiency might
improve Cxcr7/ embryo survival during
midgestation. At E13.5 we observedequivalent numbers of Cxcr7/;Adm+/+ and Cxcr7/;Adm+/
animals from compound heterozygous intercrosses (Figure 6B,
E13.5). However, at E14.5 the expected 1:1 ratio of Cxcr7/;
Adm+/+:Cxcr7/;Adm+/ mice was significantly skewed, with
<50% of the expected Cxcr7/;Adm+/+ genotype being offset
by a disproportionate survival of Cxcr7/;Adm+/ embryos
(Figure 6B, E14.5). Thus, haploinsufficiency of Adm improves
Cxcr7/ embryo survival during midgestation. It is also note-
worthy that embryonic lethality was significantly increased in
the Cxcr7+/;Adm+/ cross, which is likely due to the critical
role of AM in female reproductive physiology (Lenhart andCaron,
2012; Lenhart et al., 2014; Li et al., 2006, 2008, 2013). This
finding suggests that disruption of the parental CXCR7-AM
axis likely contributes to the severity of the phenotypes.
Next, we bred Cxcr7+/ mice to Admhi/hi animals in order
to evaluate whether AM overexpression might exacerbate
Cxcr7/ gestational loss or influence survival. Interestingly,
Figure 5. Loss of CXCR7 Causes Enlarged Dermal Lymphatics with
Decreased Branching Complexity In Vivo and Enhances LEC Prolif-
eration In Vitro
(A and B) Cxcr7/ P1 skin (n = 5) exhibit dysmorphic dermal lymphangio-
genesis compared to controls (n = 4). White asterisks identify a lacuna; yellow
dots highlight branch points. Scale bars represent 50 mM.
(C and D) Quantitation of the number of lacunae and branch points respec-
tively. Fewer lacunae and decreased branching complexity were observed in
Cxcr7/ animals. A branch point is defined as a vessel with three vessels
branching away. A lacuna is defined as a space where three or more branch
points coalesce.
(E–H) Skin of E13.5 Cxcr7/ embryos. Scale bars represent 50 mM.
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Developmewe found that postnatal survival of compound heterozygous
pups was poor, with 30% postnatal lethality, making mainte-
nance of the Cxcr7+/;Admhi/+ mouse colony very challenging.
Whereas we had not previously observed Cxcr7+/ pup lethality
in other genetic crosses, Cxcr7+/ animals that expressed a
single Admhi allele were more susceptible to death. Moreover,
homozygosity for the Admhi allele resulted in a striking 62%
lethality ofCxcr7+/;Admhi/hi mice (Figure 6D). Collectively, these
data demonstrate that titration of the endogenous AM ligand is
causally associated with profound changes in the survival of
Cxcr7 gene-targeted animals.
Haploinsufficiency of AM Normalizes Lymphatic and
Cardiac Hyperproliferation of Cxcr7–/– Mice
Based on the improved embryonic survival of Cxcr7/;Adm+/
embryos, we next performed phenotypic characterization of
lymphatic and cardiac development in these animals, with
the expectation that haploinsufficiency for AM ligand might
normalize the hypertrophic cardiovascular phenotypes of
Cxcr7 null embryos. Importantly, haploinsufficiency for AM had
no effect on the LS:JV ratio in Cxcr7+/+ animals (Figures 6E
and 6F). Consistent with Figures 3E–3G, the podoplanin-positive
lymph sacs of E13.5Cxcr7/;Adm+/+ embryos showed a signif-
icant 4-fold enlarged LS:JV ratio compared to wild-type litter-
mates (Figures 6G and 6I). However, this lymph sac enlargement
was normalized in Cxcr7/;Adm+/ mice, resulting in LS:JV
ratios that were statistically indistinguishable from wild-type
animals (Figures 6H and 6I). Additionally, we used Ki67 staining
to quantitate the number of proliferating LECs and found a direct
correlation between the proliferation of LECs and the LS:JV
ratios and genotypes. While Cxcr7/;Adm+/+ mice had sig-
nificantly more proliferating cells in the LS compared to wild-
type animals (Figures 6G and 6J), haploinsufficiency for AM
(Cxcr7/;Adm+/) allowed this hyperproliferation to revert to
levels that were equivalent to those observed in wild-type ani-
mals (Figures 6H and 6J). Taken together, these findings demon-
strate that the increase in LS:JV ratio in Cxcr7 null mice is due to
an increase in LEC proliferation that can be reversed by genetic
reduction of AM ligand.
Similar effects were observed in the developing heart. Using
BrdU incorporation assays, we quantitated the amount of prolif-
erating cells in E11.5 cardiac tissue from the AM genetic titration
animals. Percent proliferation of cardiac cells inCxcr7+/+;Adm+/
animals was equivalent to wild-type animals, demonstrating that
Adm haploinsufficiency alone does not affect heart size (Figures
7A–7D). Consistent with other studies (Gerrits et al., 2008), we
noted a statistically significant increase in proliferation of
Cxcr7/ cardiac tissue compared to wild-type (Figures 7E, 7F,
and 7I). Importantly, this aberrant cardiac hyperproliferation
was normalized to wild-type levels in Cxcr7/;Adm+/ embryos
(Figures 7G–7I). We noted increased proliferation particularly(I and J) Lymphatic vessels of P1Cxcr7/ embryos are dilated, with increased
junctional area where vessels coalesce to form a branch point. Yellow dashed
and straight line in (G) and (H) represent the vessel diameter and junctional
area, respectively, measured in P1 skin.
(K) Quantitation of LEC proliferation after a 24 hr treatment with 10 nM AM.
In (A)–(K), data are represented as mean ± SEM. *p < 0.05, **p < 0.01. See also
Figure S6.
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Figure 6. Genetic Titration of Adm Influences Cxcr7–/– Phenotypes
(A and B) Schematic of Adm genetic reduction experiment with expected and observed Mendelian ratios. Cxcr7+/;Adm+/mice were bred with Cxcr+/;Adm+/+
mice, resulting in the following expected distribution: 25% Cxcr7+/+, 50% Cxcr7+/, and 25% Cxcr7/ with 50% of each Cxcr7 genotype being AM hetero-
zygous. Observed number of animals (including resorptions) was statistically different from expected as judged by a c2 test (p = 0.02).
(C and D) Schematic ofAdm genetic increase experiment with expected and observed percentage of survival of animals, n = 85. Observed number of animals was
statistically different from expected as judged by a c2 test (p = 0.001).
(E–H) Representative images of JV and LS of E13.5 embryos from the gene reduction experiment stained for podoplanin and Ki67. Scale bars represent 100 mM.
(I) Quantitation of the LS:JV ratio in E13.5 embryos (n = 4–8 for each genotype).
(J) Percent proliferating cells in the LS (n = 4–8 for each genotype).
Data are represented as mean ± SEM. *p < 0.05, **p < 0.01 (one-way ANOVA).
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and arrowheads, respectively)—regions of the heart where
CXCR7 is highly expressed (see Figure 1F). Furthermore,
2 days after the AM-mediated peak in myocyte proliferation,
many of the hearts of Cxcr7/;Adm+/ embryos appeared
phenotypically normal and similar in size to wild-type animals
(Figures 7J–7L). We therefore conclude that genetic reduction
of AM peptide alleviates the pathological cardiac hyperprolifera-
tion of Cxcr7 null animals and ultimately impacts cardiac size
during development.
Although difficulty maintaining the line precluded extensive
timed matings, we observed even more precocious develop-
ment of the LS of Cxcr7/;Admhi/hi embryos. At E11.5,
Cxcr7/;Admhi/hi embryos often had fully formed lymph sacs
that were dramatically enlarged and blood-filled (Figure S3E).
This further exacerbated lymphatic development confirmed our536 Developmental Cell 30, 528–540, September 8, 2014 ª2014 Elsehypothesis that Cxcr7/ LS develop precociously. Hearts of
Cxcr7/ on the Admhi/hi background also tended to be enlarged
with thickened compact zones and significant blood accumula-
tion in the ventricles and atria (data not shown).
DISCUSSION
The pleiotropic consequences of CXCR7 loss have made it diffi-
cult to discern which ligand(s) are responsible for a given
phenotype. In this study, using both loss-of-function and gain-
of-function animal models, we demonstrate that several of the
essential functions of CXCR7 during cardiovascular develop-
ment can be attributed to its decoy activities for the ligand AM.
Haploinsufficiency of AM in a Cxcr7/ animal effectively
reversed cardiac and lymphatic hyperproliferation, demon-
strating that CXCR7 is required as a molecular rheostat forvier Inc.
Figure 7. Genetic Reduction of Adm Normalizes Cxcr7–/– Cardiac Proliferation and Size
(A–G) (A, C, E, and G): BrdU staining of cardiac tissue of E11.5 embryos from the gene titration experiment. Exposure, 750ms. Scale bars represent 100 mM. (B, D,
F, and H): arrows highlight proliferating epicardium, and arrowheads highlight proliferating endocardium. Exposure, 250 ms. Scale bars represent 100 mM.
(I) Percent proliferating cardiac cells in embryos from genetic reduction experiment (n = 3–5 for each genotype). Data are represented as mean ± SEM. *p < 0.05
(one-way ANOVA).
(J–L) H&E-stained cardiac tissue of E13.5 animals from the genetic reduction experiment (n = 3–5 for each genotype). Scale bars represent 100 mM.
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other atypical chemokine receptors are known to bind multiple
ligands, only recently has the repertoire of CXCR7 ligands
been expanded beyond the chemokines CXCL12 and CXCL11.
For example, a very recent study has elegantly demonstrated
that proteolytic peptide fragments of the adrenal neuropeptide
proenkaphalin A interact with CXCR7 and thereby mediate re-
sponses to glucocorticoid secretion and anxiety behaviors in
mice (Ikeda et al., 2013). Structure-function studies of the proen-
kaphalin A-derived peptides, along with our current findings on
the AM peptide, further highlight the ability of CXCR7 to bind
to several classes of small peptidergic ligands, which also
happen to be particularly enriched in the adrenal gland. Whether
adrenomedullin—which as it name implies, is also highly ex-
pressed in the adrenal gland—is also implicated in the CXCR7-
mediated glucocorticoid secretion and anxiety behaviors has
yet to be determined.
Likewise, our study does not formally rule out the involvement
of CXCL12 in the described cardiovascular hyperplasia pheno-
types of Cxcr7/ mice. Genetic deletion of either CXCR4 orDevelopmeCXCL12 has been associated with defective ventricular septum
formation (Ma et al., 1998; Zou et al., 1998). However, only
recently have studies in chick embryos demonstrated a gain-
of-function phenotype for CXCL12 overexpression in neural
crest cell migration related to cardiac development (Escot
et al., 2013). While the effects of CXCL12 overexpression might
be anticipated tomore closely parallel the effects of CXCR7 loss-
of-function, the cardiac phenotypes of these two models are
markedly different. CXCL12 misexpression in chick embryos
diverts neural crest cell migration to the heart, while CXCR7
deficiency promotes cardiac myocyte hyperplasia and septal
defects. Our current study does not preclude the functional
deregulation of CXCL12, however, it does definitively demon-
strate that genetic reduction in AM ligand is fully sufficient to
rescue the Cxcr7/ cardiac hyperplasia. Therefore, although
we cannot exclude potential effects of CXCL12 on the Cxcr7/
cardiac phenotypes, we have identified AM as the critical ligand
for mediating the cardiac hyperproliferation.
With respect to lymphangiogenesis, genetic studies in zebrafish
have also established a central role for CXCL12(SDF-1)/CXCR4ntal Cell 30, 528–540, September 8, 2014 ª2014 Elsevier Inc. 537
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network (Cha et al., 2012). Interestingly, the requirement for
CXCL12 in guiding zebrafish LEC migration occurs at develop-
mental time points that are subsequent to LEC sprouting from
the posterior cardinal vein. However, our expression studies in
mice revealed little expression of CXCR7 in LECs that have
migrated away from the jugular vein, and we failed to observe
prominent defects in the migration and assembly of lymphatic
sacs inCxcr7/mice.Although thesespatiotemporal differences
in receptor-ligand expression patterns may simply be attributed
to differences between species, a more compelling implication
of these studies is that dynamic changes in the expression of
CXCR4 and CXCR7 may be critical for orchestrating the extent
and time frame to which nascent LECs sense and respond to
different lymphangiogenic growth factors.Moreover, the dynamic
spatiotemporal expression of signaling and decoy receptors
likely provides a mechanism for individual LECs and their adja-
cent tissues to create a localized microgradient of chemotactic
or proliferative factors (Dona` et al., 2013; Venkiteswaran et al.,
2013) to promote the stepwise growth of lymphatic vessels.
Although our current study has focused on the effects of
CXCR7 on AM-mediated cardiac and lymphatic development,
it is important to recognize that the interaction of CXCR7 with
AM may initiate downstream signaling and active processes in
other cell types or tissues. For example, several studies have
pointed to potential nondecoy functions of CXCR7, such as
signaling through b-arrestin, heterodimerizing with other GPCRs
in certain tissues, and coupling with G-proteins in astrocytes
(Kapas and Clark, 1995; Odemis et al., 2012; Rajagopal et al.,
2010). Therefore, while we have currently established CXCR7
as a molecular rheostat for AM signaling during cardiovascular
development, future studies may identify potential CXCR7-
GPCR complexes that allow for functional AM signaling in other
cell types or tissues.
Our findings of increased ERK phosphorylation in dermal lym-
phatics of Cxcr7/ mice are consistent with several previously
described models with aberrant lymphangiogenesis associated
with increased ERK signaling. For example, ex vivo expression
of Spred-1/2, negative regulators of ERK activation, suppresses
LEC proliferation while double knockout mice exhibit dilated,
blood-filled lymphatics—similar to the Cxcr7/ phenotype
described by Taniguchi et al. (2007). Likewise, mice lacking
apoptosis stimulating protein of p53 (Aspp1) have increased
ERK activation and exhibit similar transient subcutaneous
edema with dilated and dysmorphic lymphatics and increases
in cardiac LYVE1+ staining (Hirashima et al., 2008). Most
recently, a fine-tuned balance between ERK and Akt signaling
pathways has been recognized as an essential component for
establishing LEC fate determination and differentiation (Deng
et al., 2013; Simons and Eichmann, 2013). Collectively, these
studies identify ERK signaling as a critical regulator of lymphan-
giogenesis and either loss or excessive ERK signal as a cause of
aberrant lymphangiogenesis. Results of this study identify a
mechanism, whereby the positioning of a decoy receptor at
the junction of lymphatic sprouting and migration serves as a
biological rheostat for regulating the migratory and mitogenic
effects of lymphangiogenic growth factors that are upstream of
ERK activation. Additional studies to determine whether and
how other atypical chemokine receptors may influence cardiac538 Developmental Cell 30, 528–540, September 8, 2014 ª2014 Elseand lymphatic development are warranted and may lead to
conceptual paradigms about how growth factor gradients and
their downstream signaling pathways can be precisely con-
trolled by 7-transmembrane decoy receptors during cardiovas-
cular development.
EXPERIMENTAL PROCEDURES
Mice
Mice that contain a GFP reporter knocked into theCxcr7 genewere purchased
(C57BL/6-Ackr3tm1Litt/J, Jackson Laboratory). Generation of Adm+/ and
Admhi/hi mice with a targeted, deletion and overexpression of Adm, respec-
tively, has been previously described (Caron and Smithies, 2001; Dackor
et al., 2006; Li et al., 2013). For timed pregnancies, Cxcr7+/ animals were in-
tercrossed with Cxcr7+/ or Cxcr7+/;Adm+/ animals. Dams were monitored
for vaginal plugs, and the day when the vaginal plug was detected was consid-
ered E0.5. Cxcr7+/;Admhi/+ animals were also intercrossed to establish sur-
vival. For BrdU incorporation assays, pregnant females were injected with
BrdU (0.1 mg/g of BW, Sigma-Aldrich) via intraperitoneal injection 2 hr prior
to dissection. All experiments involving mice were approved by the Institu-
tional Animal Care and Use Committee at The University of North Carolina at
Chapel Hill.
Cell Culture and RNAi
Human adult (HMVECdLyAd-Der) and neonatal (HMVEC-d Neo) dermal
lymphatic endothelial cells (Lonza) were cultured in EGM-2MV media.
HEK293T cells were maintained in DMEM with 10% fetal bovine serum and
1% penicillin streptomycin or gentamicin. Lentiviral particle production and
infection were performed according to standard protocol. Briefly, human
CXCR7 shRNA pLKO1 vectors (UNC Viral Core) were cotransfected into
HEK293T cells with lentiviral packaging vectors psPAX2 and MD2.G
(Addgene) using Lipofectamine 2000 (Invitrogen). Viral supernatants were
filtered, supplemented with 6 mg/ml polybrene, and used to infect LECs for
48 hr before functional assays were performed.
Gene Expression Analysis
Agilent human gene expression microarrays were performed on three inde-
pendent plates of hLECs treated with 10 nM AM (American Peptide). Analysis
was performed using the Significance Analysis of Microarrays (SAM) software
(Stanford University). For embryonic endothelial cells, CD31 positive cells were
isolated using magnetic beads. Quantitative RT-PCR was performed using
primers and probes or hCXCR7 Assays on Demand (Life Technology) after
reverse transcription of 2 mg of total RNA. For AM22-52 treatment, cells were
incubated with 1 mM AM22–52 (American Peptide Company) for 30 min prior
to treatment with 10 nM AM and 1 mM AM22–52.
Scavenger Assay
HEK293T cells were transfected with CXCR7 or pcDNA3.1 (negative control)
using standard calcium phosphate transfection. Cells were treated with bio-
tinylated-AM (Phoenix Pharmaceuticals), and aliquots of media were collected
over 8 hr. Biotinylated-AM was detected with IRDye Streptavidin (1:2,500,
Li-COR).
ERK Phosphorylation
HEK293T cells were transfected with expression plasmids, serum-starved for
20 hr, and treatedwith vehicle or 10 nMAM for 1min. Blots were blocked in 5%
BSA, probed overnight with monoclonal rabbit anti-mouse pERK and tERK
(1:1000, Cell Signaling) and monoclonal mouse anti-GAPDH (1:2000, Novus
Biologicals), incubated in appropriate secondary antibody, and imaged on
the Odyssey scanner (Li-COR). A blot with three independent experiments
run on the same gel was used to perform statistical analysis.
Immunohistochemistry
Embryo sections andwholemount tissuewerepermeabilized, blockedwith 5%
normal donkey serum, and incubated overnight at room temperature with pri-
mary antibodies, and then probed with appropriate secondary antibodies.
Antibodies are described in the Supplemental Experimental Procedures.vier Inc.
Developmental Cell
CXCR7-AM Axis in Cardiovascular DevelopmentQuantitation of LS:JV Ratio and Blood and Protein Accumulation
in LS
Transverse sections of jugular lymph sacs of wild-type and mutant mice
were hematoxylin and eosin (H&E) stained. The area of the LS and JV
were measured using ImageJ software (NIH), and sections were graded
for blood and protein accumulation in the LS using a scoring rubric.
Blood and protein were graded as follows: 0 = no red blood cells (RBC);
1 = 3–10 RBC; 2 = 3–50 RBCs; 3 = >50 RBCs; 0 = no protein; 1 = minimal
protein accumulation; 2 = moderate protein accumulation; 3 = extensive
protein accumulation. Brightfield images were taken on a Leitz Dialux 20
Microscope.
In Vitro Migration and Proliferation Assays
Scratch Assay
CXCR7 knockdown (and negative control) LECs were grown to conflu-
ence and then scratched with a pipette tip. LECs were rinsed with PBS to
remove nonadherent cells and then treated in 0.5% FBS RPMI with vehicle
or 10 nM AM. Four fields per well were imaged at T = 0 hr and at
T = 18 hr postscratch using an Olympus IX-81 inverted microscope equipped
with a QImaging Retiga 4000R camera at 43 magnification. The percent
change in migration was calculated by measuring the open area of the
scratch (ImageJ). Results shown are representative of three independent
experiments.
Transwell Migration Assay
HEK293T cells transfected with expression plasmids and LECs with lentivi-
ral-induced CXCR7 knockdown were labeled with 5 mM Cell Tracker Green
(CTG) CMFDA (Life Technologies). Cells (1 3 105) were treated with 10 nM
AM for 5 min and then seeded onto 8 mm transwell inserts (BD Biosciences).
After 4 hr incubation, inserts were fixed with 4% PFA, and filters were
mounted for analysis. Quantitation of transmigrated cells was done by
measuring the threshold of CTG-labeled cell fluorescence using ImageJ
(NIH).
Proliferation
CXCR7 knockdown and control LECswere plated, serum starved for 4 hr, then
treated with 10 nM AM for 24 hr. Cells counts were assessed using a Countess
Automated Cell counter (Life Technology).
Statistical Analysis
Student’s two-tailed t test was used for all comparisons unless otherwise
noted in the corresponding figure legend.
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